nor-NOHA Acetate: Arginase Inhibition in Cancer & Endothelial Models

Executive Summary: nor-NOHA (acetate) is a chemically defined, reversible arginase inhibitor (Ki 0.5 μM) shown to block arginase activity in rat liver extracts (APExBIO). In vitro, it inhibits HepG2 proliferation, promotes apoptosis, and modulates key cancer-related proteins. In vivo evidence demonstrates restoration of endothelial function and normalization of nitric oxide pathways without altering underlying arthritis severity. These data clarify arginase’s role at the intersection of immune metabolism and tumor biology. This article contrasts recent mechanistic insights with prior reports and offers protocol details for research use.

Biological Rationale

Arginase is a central enzyme in the urea cycle, catalyzing the hydrolysis of L-arginine to urea and L-ornithine. This reaction competes directly with nitric oxide synthase (NOS), which uses L-arginine to generate nitric oxide (NO), a molecule critical for vascular tone, immune signaling, and tumor microenvironment regulation (APExBIO). Increased arginase activity can deplete local arginine, limiting NO production and contributing to immune suppression and tumor progression. In cancer, elevated arginase expression is linked to reduced T cell activity and enhanced metastatic potential, while in endothelial dysfunction, arginase-driven arginine depletion impairs NO-mediated vasodilation. Targeting arginase is thus a rational approach for modulating both cancer cell behavior and immune/endothelial interactions (see detailed mechanistic review).

Mechanism of Action of nor-NOHA (acetate)

nor-NOHA (acetate), formally named 2S-amino-4-[[(hydroxyamino)iminomethyl]amino]-butanoic acid, diacetate, is a potent and reversible arginase inhibitor with a reported Ki of 0.5 μM for rat liver arginase (product documentation). By binding to the arginase active site, nor-NOHA competitively blocks L-arginine hydrolysis, resulting in increased availability of arginine for NOS-mediated NO synthesis. This biochemical shift can enhance NO production, restore endothelial responses, and affect downstream signaling pathways involved in inflammation, apoptosis, and cell migration. In cancer cells, arginase inhibition by nor-NOHA upregulates tumor suppressor proteins (e.g., P53), downregulates invasion markers (e.g., MMP-2), and increases E-cadherin, supporting anti-migratory and pro-apoptotic effects (see workflow integration).

Evidence & Benchmarks

• nor-NOHA (acetate) inhibits rat liver arginase with a Ki of 0.5 μM; reversible binding confirmed in cell-free enzyme assays (APExBIO).
• In vitro, nor-NOHA treatment of HepG2 cells reduces proliferation, induces apoptosis, and increases P53 and E-cadherin expression, while suppressing Arg1 and MMP-2, markers linked to invasion and migration (article extends prior mechanistic reports by quantifying protein shifts).
• In vivo, administration of nor-NOHA restored endothelial function in rat models of adjuvant-induced arthritis by increasing NOS activity and EDHF signaling, decreasing superoxide anion levels, and reducing plasma IL-6 and VEGF concentrations; arthritis severity was not affected (APExBIO).
• nor-NOHA does not directly modulate CD36-driven lipid signaling or innate immune escape pathways in AML, as recently clarified by Guo et al. (Cell Rep Med, 2024), distinguishing arginase-targeted from lipid metabolism-targeted approaches.
• Benchmarked as a lyophilized powder (MW 296.3, purity ≥97%), nor-NOHA (acetate) is soluble to 5 mg/ml in DMSO and 1 mg/ml in DMF; solutions should be freshly prepared and stored at -20°C (APExBIO).

Applications, Limits & Misconceptions

nor-NOHA (acetate) is primarily used for dissecting the roles of arginase in cancer biology, immunometabolism, and endothelial dysfunction. Its specificity and reversibility enable precise modulation of L-arginine availability and downstream NO signaling, making it a valuable tool for both cell-based and animal research. Notably, nor-NOHA does not directly interfere with CD36-mediated lipid metabolic pathways, which have been implicated in immune escape and resistance to hypomethylating agents in acute myeloid leukemia, as detailed by Guo et al. (this article clarifies the metabolic axis beyond arginase).

Common Pitfalls or Misconceptions

• nor-NOHA (acetate) is not a direct modulator of CD36-driven innate immune pathways; its effects are limited to arginase and arginine metabolism.
• It does not reduce the severity of arthritis in vivo, despite improving endothelial markers; disease-modifying effects are not observed (APExBIO).
• No clinical trials involving nor-NOHA (acetate) are reported to date; all efficacy and mechanistic data are from preclinical models.
• Activity benchmarks refer to rat liver or HepG2 cell models; cross-species or tissue-specific differences may occur.
• Improper storage or repeated freeze-thaw can degrade compound potency; solutions must be used promptly after reconstitution.

Workflow Integration & Parameters

Protocol Parameters

• In vitro use (HepG2 cells): nor-NOHA (acetate) is applied at concentrations of 1–100 μM in serum-containing media; typical exposure is 24–48 hours to observe apoptosis and proliferation effects (see protocol details).
• In vivo dosing (rat models): nor-NOHA is administered by intraperitoneal injection, dosed according to body weight (e.g., 10–40 mg/kg), with daily injections for up to 14 days in arthritis models (APExBIO).
• Solution preparation: Dissolve lyophilized powder up to 5 mg/ml in DMSO or 1 mg/ml in DMF; filter-sterilize and aliquot for single use. Store unused powder at -20°C.
• Shipping & handling: Shipped on blue ice; avoid repeated freeze-thaw to maintain stability.
• Controls: Include vehicle and inactive analog controls in all experiments to verify arginase-specific effects.

For extended protocol guidance and troubleshooting, see this step-by-step workflow guide, which details cell line selection, compound handling, and readout optimization.

Conclusion & Outlook

nor-NOHA (acetate) provides a robust, reversible tool for dissecting the role of arginase in cancer and vascular biology. It enables precise modulation of arginine metabolism and NO signaling, underpinning studies of apoptosis, invasion, and immune cell function. Importantly, nor-NOHA acts via arginase inhibition, not via direct modulation of CD36-driven lipid immune pathways, thus complementing but not replacing approaches that target metabolic-immune axes in AML or other cancers. Future research may combine nor-NOHA with agents that target parallel metabolic or immunosuppressive pathways, but current data support its utility primarily in bench research and preclinical models (Cell Rep Med, 2024). For additional context, see how this article updates the application scope described in earlier benchmarking reports.